Adverse Event Reporting in Publications Compared With Sponsor Database for Cancer Clinical Trials
The DOI matches its Crossref record.
Abstract
Purpose: Prospectively planned collection and analysis of adverse event (AE) data are essential parts of well-conducted clinical trials. The AE data in a trial sponsor's database should be comparable with what is stipulated in the protocol and with the AE data published. We examined whether the published AE data differ from those in the sponsor's database and from the data collection requirements stated in study protocols. Methods: We searched the National Cancer Institute (NCI) Clinical Data Update System (CDUS) for studies that used the Common Toxicity Criteria version 2.0 and for which a final study publication was available. We extracted from the protocols information pertaining to AE collection and reporting methods and compared it with the methods cited in the article. We also compared the AE data in the trial publication with the AE data submitted by the investigators to CDUS. Results: We identified 22 studies meeting the criteria for this review. There was considerable inconsistency between AE collection and reporting methods cited in the protocols versus final publications. AE data in the article and CDUS were not identical. Twenty-seven percent of article high-grade AEs could not be matched to agent-attributable AEs in the CDUS. Twenty-eight percent of CDUS high-grade AEs could not be matched to AEs in the corresponding article. In 14 of 22 articles, the number of high-grade AEs in CDUS differed from the number in the articles by 20% or more. Conclusion: Lack of consistency in and reporting of AEs are associated with NCI database and trial publication AE data discrepancy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gotzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · BMJ · doi:10.1136/bmj.c869 · Cited by 8,883
SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Laupacis, A., Gøtzsche, P. C., Krleža-Jerić, K., Hróbjartsson, A., Mann, H., Dickersin, K., Berlin, J. A., et al. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-3-201302050-00583 · Cited by 7,363
“Many protocols for randomized trials do not adequately describe the primary outcomes (inadequate for 25% of trials) (18, 19), treatment allocation methods (inadequate for 54% to 79%) (20, 21), use of blinding (inadequate for 9% to 34%) (21, 22), methods for reporting adverse events (inadequate for 41%) (23), component…”
BackgroundSPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
Chan, A.-W., Tetzlaff, J. M., Gotzsche, P. C., Altman, D. G., Mann, H., Berlin, J. A., Dickersin, K., Hrobjartsson, A., Schulz, K. F., Parulekar, W. R., et al. (2013) · BMJ · doi:10.1136/bmj.e7586 · Cited by 6,251
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2012) · International Journal of Surgery · doi:10.1016/j.ijsu.2011.10.001 · Cited by 2,345
Moher, D., Hopewell, S., Schulz, K. F., Montori, V., Gøtzsche, P. C., Devereaux, P. J., Elbourne, D., Egger, M., & Altman, D. G. (2010) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.004 · Cited by 1,858
Dissemination and publication of research findings: an updated review of related biases
Song, F., Parekh, Hooper, L., Loke, Y., Ryder, J., Sutton, A., Hing, C., Kwok, C., Pang, C., & Harvey, I. (2010) · Health Technology Assessment · doi:10.3310/hta14080 · Cited by 1,039
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
Force, T., Krause, D. S., & Van Etten, R. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2106 · Cited by 801
PRISMA harms checklist: improving harms reporting in systematic reviews
Zorzela, L., Loke, Y. K., Ioannidis, J. P., Golder, S., Santaguida, P., Altman, D. G., Moher, D., Vohra, S., & PRISMA harms group (2016) · BMJ · doi:10.1136/bmj.i157 · Cited by 557
Pearce, A., Haas, M., Viney, R., Pearson, S.-A., Haywood, P., Brown, C., & Ward, R. (2017) · PLOS ONE · doi:10.1371/journal.pone.0184360 · Cited by 534
Crew, K. D., Greenlee, H., Capodice, J., Raptis, G., Brafman, L., Fuentes, D., Sierra, A., & Hershman, D. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.7573 · Cited by 478
Leombruno, J. P., Einarson, T. R., & Keystone, E. C. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091025 · Cited by 362
Patient-Reported Outcomes and the Evolution of Adverse Event Reporting in Oncology
Trotti, A., Colevas, A. D., Setser, A., & Basch, E. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4784 · Cited by 329
Self-citationSPIRIT 2013: new guidance for content of clinical trial protocols
Chan, A.-W., Tetzlaff, J. M., Altman, D. G., Dickersin, K., & Moher, D. (2013) · The Lancet · doi:10.1016/s0140-6736(12)62160-6 · Cited by 298
Golder, S., Loke, Y. K., Wright, K., & Norman, G. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002127 · Cited by 277
“There were 11 included studies that compared the actual numbers of adverse events, such as number of deaths or number of suicides [16,18,22,25,26,28,34,36,38,40,46] (S4 Table) (although in 2 studies the numbers were not explicitly reported).”
BackgroundComparison of protocols and registry entries to published reports for randomised controlled trials
Dwan, K., Altman, D. G., Cresswell, L., Blundell, M., Gamble, C. L., & Williamson, P. R. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000031.pub2 · Cited by 243
CONSORT 2025 explanation and elaboration: updated guideline for reporting randomised trials
Hopewell, S., Chan, A.-W., Collins, G. S., Hróbjartsson, A., Moher, D., Schulz, K. F., Tunn, R., Aggarwal, R., Berkwits, M., Berlin, J. A., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081124 · Cited by 205
Bias, Spin, and Misreporting: Time for Full Access to Trial Protocols and Results
Chan, A.-W. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050230 · Cited by 144
“trial protocols from research ethics committees [13–16], funding agencies [17], research groups [18,19], and”
BackgroundReview and publication of protocol submissions to Trials – what have we learned in 10 years?
Li, T., Boutron, I., Salman, R. A.-S., Cobo, E., Flemyng, E., Grimshaw, J. M., & Altman, D. G. (2017) · Trials · doi:10.1186/s13063-016-1743-0 · Cited by 66
Norris, S. L., Moher, D., Reeves, B. C., Shea, B., Loke, Y., Garner, S., Anderson, L., Tugwell, P., & Wells, G. (2013) · Research Synthesis Methods · doi:10.1002/jrsm.1062 · Cited by 50
Blumle, A., Meerpohl, J. J., Rucker, G., Antes, G., Schumacher, M., & von Elm, E. (2011) · BMJ · doi:10.1136/bmj.d1828 · Cited by 44
“Differences between protocols and publications were also found for the reporting of allocation concealment and adverse events.”
BackgroundTan, Z. W., Tan, A. C., Li, T., Harris, I., Naylor, J. M., Siebelt, M., van Tiel, J., Pinheiro, M., Harris, L., Chamberlain, K., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-038283 · Cited by 37
Le-Rademacher, J., Hillman, S. L., Meyers, J., Loprinzi, C. L., Limburg, P. J., & Mandrekar, S. J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx043 · Cited by 24
“Scharf O, Colevas AD.”
BackgroundGryaznov, D., von Niederhäusern, B., Speich, B., Kasenda, B., Ojeda-Ruiz, E., Blümle, A., Schandelmaier, S., Mertz, D., Odutayo, A., Tomonaga, Y., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-053417 · Cited by 22
Speich, B., Odutayo, A., Peckham, N., Ooms, A., Stokes, J. R., Saccilotto, R., Gryaznov, D., von Niederhäusern, B., Copsey, B., Altman, D. G., et al. (2022) · Trials · doi:10.1186/s13063-022-06516-1 · Cited by 21
Metadata
- Authors
- Scharf, O., & Colevas, A. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-08-20
- Volume
- 24
- Issue
- 24
- Pages
- 3933-3938
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165690041
- Cited by
- 109
- References
- 0
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.